BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 26163823)

  • 1. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
    Hong SK; Wu PK; Karkhanis M; Park JI
    Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mortalin/HSPA9-mediated switch in tumor-suppressive signaling of Raf/MEK/extracellular signal-regulated kinase.
    Wu PK; Hong SK; Veeranki S; Karkhanis M; Starenki D; Plaza JA; Park JI
    Mol Cell Biol; 2013 Oct; 33(20):4051-67. PubMed ID: 23959801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1).
    Dwivedi Y; Rizavi HS; Zhang H; Roberts RC; Conley RR; Pandey GN
    Int J Neuropsychopharmacol; 2009 Nov; 12(10):1337-54. PubMed ID: 19835659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
    Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in
    Wu PK; Hong SK; Park JI
    Mol Cell Biol; 2017 Sep; 37(18):. PubMed ID: 28674184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
    Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
    Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal.
    Catalanotti F; Reyes G; Jesenberger V; Galabova-Kovacs G; de Matos Simoes R; Carugo O; Baccarini M
    Nat Struct Mol Biol; 2009 Mar; 16(3):294-303. PubMed ID: 19219045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sp1 regulates Raf/MEK/ERK-induced p21(CIP1) transcription in TP53-mutated cancer cells.
    Karkhanis M; Park JI
    Cell Signal; 2015 Mar; 27(3):479-86. PubMed ID: 25595558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
    Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
    Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic AMP signaling reduces sirtuin 6 expression in non-small cell lung cancer cells by promoting ubiquitin-proteasomal degradation via inhibition of the Raf-MEK-ERK (Raf/mitogen-activated extracellular signal-regulated kinase/extracellular signal-regulated kinase) pathway.
    Kim EJ; Juhnn YS
    J Biol Chem; 2015 Apr; 290(15):9604-13. PubMed ID: 25713071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raf/MEK/ERK can regulate cellular levels of LC3B and SQSTM1/p62 at expression levels.
    Kim JH; Hong SK; Wu PK; Richards AL; Jackson WT; Park JI
    Exp Cell Res; 2014 Oct; 327(2):340-52. PubMed ID: 25128814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2.
    Piao C; Jin M; Kim HB; Lee SM; Amatya PN; Hyun JW; Chang IY; You HJ
    Oncogene; 2009 May; 28(21):2173-84. PubMed ID: 19398949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IQGAP1 is a scaffold for mitogen-activated protein kinase signaling.
    Roy M; Li Z; Sacks DB
    Mol Cell Biol; 2005 Sep; 25(18):7940-52. PubMed ID: 16135787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Leydig cell MEK/ERK pathway is critical for maintaining a functional population of adult Leydig cells and for fertility.
    Yamashita S; Tai P; Charron J; Ko C; Ascoli M
    Mol Endocrinol; 2011 Jul; 25(7):1211-22. PubMed ID: 21527500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biology and clinical development of MEK inhibitors for cancer.
    Luke JJ; Ott PA; Shapiro GI
    Drugs; 2014 Dec; 74(18):2111-28. PubMed ID: 25414119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
    Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
    Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK1 and MEK2 differentially control the duration and amplitude of the ERK cascade response.
    Kocieniewski P; Lipniacki T
    Phys Biol; 2013 Jun; 10(3):035006. PubMed ID: 23735655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential regulation of mitogen-activated protein/ERK kinase (MEK)1 and MEK2 and activation by a Ras-independent mechanism.
    Xu S; Khoo S; Dang A; Witt S; Do V; Zhen E; Schaefer EM; Cobb MH
    Mol Endocrinol; 1997 Oct; 11(11):1618-25. PubMed ID: 9328344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition.
    Yao W; Oh YT; Deng J; Yue P; Deng L; Huang H; Zhou W; Sun SY
    J Biol Chem; 2016 Oct; 291(41):21694-21702. PubMed ID: 27576686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.